To identify genes that may be relevant to the molecular action of antidepressants, we investigated transcriptional changes induced by the selective serotonin reuptake inhibitor paroxetine in a serotonergic cell line. We examined gene expression changes after acute treatment with paroxetine and sought to validate microarray results by quantitative PCR (qPCR). Concordant transcriptional changes were confirmed for 14 genes by qPCR and five of these, including the adrenomedullin gene (Adm), either approached or reached statistical significance. Reporter gene assays showed that a SNP (rs11042725) in the upstream flanking region of ADM significantly altered expression. Association analysis demonstrated rs11042725 to be significantly associated wi...
Pharmacogenomics is a developing area of biomedical research that aims to identify genetic variants ...
The majority of antidepressant drugs act by increasing synaptic serotonin levels in the brain. Genet...
BACKGROUND: In major depressive disorder, selective serotonin reuptake inhibitors target the seroton...
Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder MDD. Its metabolis...
[[abstract]]Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD)....
[[abstract]]Antidepressant paroxetine is a serotonin reuptake inhibitor used in the treatm...
Major depressive disorder is one of the most common and debilitating psychiatric disorders. Psychoph...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Predicting antidepressant response has been a clinical challenge for mood disorder. Although several...
Objective: The mechanism of action of antidepressant drugs is not fully understood. Application of ...
It has been difficult to identify genes affecting drug response to Selective Serotonin Reuptake Inhi...
Predicting antidepressant response has been a clinical challenge for mood disorder. Although several...
Major depressive disorder is one of the most common and debilitating psychiatric disorders. While p...
Background: The unwanted side effects associated with antidepressants are key determinants of treatm...
Atomoxetine, a selective inhibitor of the norepinephrine transporter, exerts its therapeutic effect ...
Pharmacogenomics is a developing area of biomedical research that aims to identify genetic variants ...
The majority of antidepressant drugs act by increasing synaptic serotonin levels in the brain. Genet...
BACKGROUND: In major depressive disorder, selective serotonin reuptake inhibitors target the seroton...
Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder MDD. Its metabolis...
[[abstract]]Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD)....
[[abstract]]Antidepressant paroxetine is a serotonin reuptake inhibitor used in the treatm...
Major depressive disorder is one of the most common and debilitating psychiatric disorders. Psychoph...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Predicting antidepressant response has been a clinical challenge for mood disorder. Although several...
Objective: The mechanism of action of antidepressant drugs is not fully understood. Application of ...
It has been difficult to identify genes affecting drug response to Selective Serotonin Reuptake Inhi...
Predicting antidepressant response has been a clinical challenge for mood disorder. Although several...
Major depressive disorder is one of the most common and debilitating psychiatric disorders. While p...
Background: The unwanted side effects associated with antidepressants are key determinants of treatm...
Atomoxetine, a selective inhibitor of the norepinephrine transporter, exerts its therapeutic effect ...
Pharmacogenomics is a developing area of biomedical research that aims to identify genetic variants ...
The majority of antidepressant drugs act by increasing synaptic serotonin levels in the brain. Genet...
BACKGROUND: In major depressive disorder, selective serotonin reuptake inhibitors target the seroton...